Table 3 Comparison of parameters between patients with and without morphological improvement
Characteristics | Patients with morphological improvement (n = 13) | Patients without morphological improvement (n = 22) | P |
|---|---|---|---|
Age(years) | 34.46 ± 9.404 | 36.82 ± 9.620 | 0.544a |
Gender(male/female) | 7/6 | 7/15 | 0.288b |
Eye(right/left) | 3/10 | 10/12 | 0.282b |
Anti-VEGF(bevacizumab/ranibizumab) | 3/10 | 7/15 | 0.709b |
Duration of disease(weeks) | 21.53 ± 11.85 | 25.86 ± 18.04 | 0.775c |
Number of injections(times) | 2.23 ± 0.725 | 2.50 ± 0.802 | 0.335c |
Baseline BCVA(letters) | 63.00 ± 14.24 | 52.18 ± 12.73 | 0.026a* |
Baseline CRT(μm) | 347.9 ± 104.1 | 357.0 ± 97.73 | 0.649c |
BCVA improvement(letters) | 14.69 ± 13.51 | 18.55 ± 19.35 | 0.257c |
CRT decrease(μm) | 99.77 ± 89.55 | 69.18 ± 80.89 | 0.287c |